Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409240 · ClinicalTrials.gov registry record · Phase 3
Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
A Phase 3 study, sponsored by Providence VA Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT00409240 is a Phase 3 study that has completed, run by Providence VA Medical Center. The registered enrollment target is 103 participants.
The verdict
NCT00409240, a Phase 3 study, has completed, sponsored by Providence VA Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood pressure.
Interventions
- OTHER MEDIC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409240
The ClinicalTrials.gov registry entry for NCT00409240 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence VA Medical Center, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDIC is the first listed.
NCT00409240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00409240 about?
NCT00409240 is a clinical study titled "Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes". Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood pressure.
What is the current status of trial NCT00409240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2006-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00409240?
The interventions under investigation include: MEDIC (OTHER).
Who is sponsoring clinical trial NCT00409240?
This trial is sponsored by Providence VA Medical Center, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.